MRK dividend yield: 3.25%. TXN dividend yield: 2.82%. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s. Texas Instruments is a semiconductor company with 21+ consecutive years of dividend increases. Its analog and embedded processing chips are used across industrial, automotive, and consumer electronics. TXN's capital management philosophy prioritizes returning all free cash flow to shareholders via dividends and buybacks.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
Texas Instruments is a semiconductor company with 21+ consecutive years of dividend increases. Its analog and embedded processing chips are used across industrial, automotive, and consumer electronics. TXN's capital management philosophy prioritizes returning all free cash flow to shareholders via dividends and buybacks.
MRK currently offers a 3.25% yield (3.08/share/year) while TXN offers 2.82% (5.20/share/year). MRK provides higher current income. However, TXN has grown its dividend faster (13.1% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in MRK vs TXN earn per year?
With $10,000 invested today: MRK pays approximately $325/year. TXN pays approximately $282/year. With DRIP reinvestment over 10 years, these grow to $950/year (MRK) and $1,483/year (TXN).
Does MRK or TXN pay monthly dividends?
MRK pays quarterly dividends. TXN pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this MRK vs TXN comparison by email
Save your analysis + get weekly dividend insights. Free forever.